Complementary and alternative (CAM) dietary therapies for cancer
The Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada. Pediatric Blood & Cancer
(Impact Factor: 2.39).
02/2008; 50(2 Suppl):494-7; discussion 498. DOI: 10.1002/pbc.21401
Complementary and alternative (CAM) therapies include a wide spectrum of dietary practices, some of which are claimed to cure cancer. Observational studies have shown consistently that predominantly plant-based diets reduce the risk for some adult type cancers such as breast cancer and prostate cancer. These studies form the basis of the American Cancer Society (ACS) nutritional guidelines. Many CAM diets prescribe a similar low fat, high fiber, high fruit and vegetable type diet, but also add detoxification and many different supplements to the basic diet which is then claimed to cure cancer. The potential advantages and disadvantages of CAM diets are discussed. Many aspects can be potentially harmful, particularly to the child with cancer. Advantages include involvement of the child and family in decision-making and care. There is no evidence to support the claims that CAM dietary therapies cure cancer.
Available from: repositorio-aberto.up.pt
Available from: link.springer.com
[Show abstract] [Hide abstract]
This study established two-dimensional gel electrophoresis (2-DE) profiles for human well-differentiated laryngeal squamous cell carcinoma tissue and paired normal mucosa epithelia tissue and identified proteins with different expressions. Well-resolved and reproducible 2-DE patterns of well-differentiated laryngeal squamous cell carcinoma and adjacent normal mucosa were obtained.
Thirteen proteins were preliminarily identified, among which ten proteins including cofilin-1, nuclear body protein SP140, GRP94, HSP 90, GSTP1-1, superoxide dismutase [Mn], cyclophilin A, proteasome activator complex subunit 2, apolipoprotein A-I precursor, and CaM-like protein were upregulated and three proteins including fatty acid-binding protein (E-FABP), calgranulin A, and calgranulin B were downregulated in laryngeal cancer tissue. The different expressions of cyclophilin A and MRP8 were confirmed by Western blotting.
We first identified 13 proteins that might be associated with the tumorigenesis of the laryngeal squamous cell carcinoma. Some proteins were the products of oncogenes and apoptosis and others were related to signal transduction and immune defense. These extensive protein variations indicated that multiple protein molecules were simultaneously involved in the oncogenesis of laryngeal cancer, which in turn is a basis for the rational designs of diagnostic and therapeutic methods.
[Show abstract] [Hide abstract]
ABSTRACT: Today still only 50% of newly diagnosed cancers can be cured. While molecular mechanisms of cell proliferation are being studied intensively, comparably little research energy, however, has been spent on unravelling metabolic interactions of cancer and host tissues. Evidence is accumulating that systemic as well as local metabolic patterns have considerable impact on tumour growth, as well as on body composition and organ functions. This may lead to new treatments in oncology. Cancer development - and recurrence - may be inhibited by physical activity, as well as by avoiding obesity, the metabolic syndrome and insulin resistance. Antineoplastic treatments induce reductions in nutritional intake and require individually tailored nutritional support. New concepts are being considered to metabolically starve or reprogram cancer cells. During palliative treatment of progressive tumours, it should be good clinical practice to avoid or treat malnutrition and chronic inflammatory states. At late stages, the primary goal should be symptomatic relief and attention to subjective individual needs.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.